P
Ph. Gabriel Steg
Researcher at National Institutes of Health
Publications - 86
Citations - 5304
Ph. Gabriel Steg is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Myocardial infarction & Acute coronary syndrome. The author has an hindex of 34, co-authored 86 publications receiving 4366 citations. Previous affiliations of Ph. Gabriel Steg include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry.
Ph. Gabriel Steg,Ph. Gabriel Steg,Nicola Greenlaw,Jean-Claude Tardif,Michal Tendera,Ian Ford,Stefan Kääb,Hélène Abergel,Hélène Abergel,Kim Fox,Roberto Ferrari +10 more
TL;DR: The risk profiles of women and men with stable CAD differ substantially and further research is needed to better understand gender determinants of outcome and devise strategies to minimize bias in the management and treatment of women.
Journal ArticleDOI
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
Matthew A. Cavender,Ph. Gabriel Steg,Sidney C. Smith,Kim A. Eagle,E. Magnus Ohman,Shinya Goto,Julia F Kuder,KyungAh Im,Peter W.F. Wilson,Deepak L. Bhatt +9 more
TL;DR: In this article, the authors describe cardiovascular outcomes at 4 years and identify predictors of these events in patients with diabetes mellitus in the Reduction of Atherothrombosis for Continued Health (REACH) registry.
Journal ArticleDOI
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
Marc P. Bonaca,Deepak L. Bhatt,Robert F. Storey,Ph. Gabriel Steg,Marc Cohen,Julia F Kuder,Erica L. Goodrich,Jose C. Nicolau,Alexander Parkhomenko,Jose Lopez-Sendon,Mikael Dellborg,Anthony J. Dalby,Jindřich Špinar,Philip E. Aylward,Ramón Corbalán,Maria Teresa B. Abola,Eva C. Jensen,Peter Held,Eugene Braunwald,Marc S. Sabatine +19 more
TL;DR: Among stable patients with prior MI, those with concomitant PAD have heightened ischemic risk, and ticagrelor reduced MACE, with a large absolute risk reduction, and MALE, and the 60-mg dose had particularly favorable outcomes for CV and all-cause mortality.
Journal ArticleDOI
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Vera Bittner,Michael Szarek,Philip E. Aylward,Deepak L. Bhatt,Rafael Diaz,Jay M. Edelberg,Zlatko Fras,Shaun G. Goodman,Sigrun Halvorsen,Corinne Hanotin,Robert A. Harrington,J. Wouter Jukema,Virginie Loizeau,Patrick M. Moriarty,Angele Moryusef,Robert Pordy,Matthew T. Roe,Peter Sinnaeve,Sotirios Tsimikas,Robert Vogel,Harvey D. White,Doron Zahger,Andreas M. Zeiher,Ph. Gabriel Steg,Gregory G. Schwartz,Odyssey Outcomes Committees,Investigators +26 more
TL;DR: Baseline lipoprotein(a) levels and corrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS, which suggests that lipoproteins should be an independent treatment target after ACS.
Journal ArticleDOI
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
Deepak L. Bhatt,Ph. Gabriel Steg,Michael Miller,Eliot A. Brinton,Terry A. Jacobson,Steven B. Ketchum,Ralph T. Doyle,Rebecca A. Juliano,Lixia Jiao,Craig Granowitz,Jean-Claude Tardif,John Gregson,Stuart J. Pocock,Christie M. Ballantyne,Reduce-It Investigators +14 more
TL;DR: Among statin-treated patients with elevated triglycerides and cardiovascular disease or diabetes, multiple statistical models demonstrate that icosapent ethyl substantially reduces the burden of first, subsequent, and total ischemic events.